The Treasury proposal under the COINS Act, published in the Federal Register on Monday, covers biotech and "super intelligence systems" and would apply to some U.S. investments above $50,000. Comments are due Dec. 7. China's commerce ministry reserves the right to retaliate.
The trade truce between Washington and Beijing was built on lists of products. The next test of it is a list of technologies, and as of Monday it has a deadline.
The Treasury Department's proposed rule implementing the COINS Act was published in the Federal Register on Monday, opening a public comment period that ends Dec. 7. Congress passed the act as part of the fiscal 2026 defense authorization law. Treasury first issued the proposal on Oct. 22.
The rule sets out two regimes, one requiring U.S. investors to notify the government of certain transactions in China and one prohibiting others. Its technical specifications cover semiconductors and microelectronics, quantum technology, "super intelligence systems," hypersonics, high-performance computing and supercomputing, and biotechnology. It would apply only to investments above $50,000, and it is not yet in force. Treasury will set an effective date when it issues final regulations after the comment period.
Beijing's response
China's Ministry of Commerce answered over the weekend. It said the proposal "discriminatorily" widened restrictions on China-related investment, that it "firmly opposed" it, and that it reserved the right to take unspecified countermeasures. The ministry called the plan an excessive use of national security concerns, expressed "grave concern" and said it runs counter to "the important consensus reached by the two heads of state."
That last phrase is the one investors should note. It ties a technical rule to the meeting between President Donald Trump and President Xi Jinping, after which the two governments released lists of nonsensitive products worth $60 billion that would receive tariff cuts.
Codification or escalation
The case that this is manageable rests on the rule itself. Washington has restricted some outbound investment in Chinese technology before, and much of the proposal puts that program on a statutory footing. Nothing takes effect until final rules are written, small investments are exempt, and Beijing's statements name no specific countermeasure.
The case that it matters rests on scope and language. Biotechnology is a significant addition to a regime that has centered on chips and computing, and U.S. venture, private equity and pharmaceutical investors have deep ties to Chinese drug developers. By invoking the leaders' consensus, Beijing has framed a notice-and-comment rule as a question about whether the truce holds.
Where it would show up
The first transmission is to capital flows. U.S. funds investing in Chinese technology and biotech companies would face new filing requirements or outright bans in covered areas. Hong Kong-listed biotech and technology shares, and the funds that hold them, are the most direct market exposure. Hong Kong's Hang Seng index rose 0.51% on Monday, giving no sign of a broad reaction.
The second is retaliation risk. Possible levers include export controls and changes to purchase commitments. The ministry has not said what it is considering, and any read-across to U.S. chipmakers or drug companies with China exposure would depend on what, if anything, it does.
The timing is sensitive for Beijing as well. The Communist Party's Fifth Plenum opened on Monday and runs through Oct. 29, and China's currency reached a four-year high the same day.
What to watch
The comment record before Dec. 7 and the rule's full technical definitions, any statement from the U.S. trade representative or Commerce Department, whether Beijing attaches a specific measure to its warning, and any economic language from the Plenum.